Chair and Department of General and Colorectal Surgery, Medical University in ŁódźKierownik: prof. dr hab.
References
1. World Cancer Research Fund and American Institute for Cancer Research Food. Nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, (DC): American Institute for Cancer Research; 2007.
2.
3.
4. Bamias A, Basdanis G, Xanthakis I et al.: Prognostic factors in patients with colorectal cancer receiving adjuvant chemotherapy or hemoradiotherapy: a pooled analysis of two randomized studies. In J Gastrointest Cancer 2005; 36: 29-38.
5. Compton C, Fenoglio-Preiser CM, Pettigrew N et al.: American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 2000; 88: 1739-57.
6. Hayashi M, Inoue Y, Komeda K et al.: Clinicopathological analysis of recurrence patterns and prognostic factors for survival after hepatectomy for colorectal liver metastasis. BMC Surg 2010; 10: 27.
7. Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287-12.
8. Ashworth TR (1869): A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Australian Medical Journal 14: 146-47.
9. Maheswaran S, Haber D: Circulating tumor cells: a window into cancer biology and metastasis. Curr Opin Genet Dev 2010; 20: 96-99.
10. Elshimali YI, Grody WW : The clinical significance of circulating tumor cells in the peripheral blood. Diagn Mol Pathol 2006; 15: 187-94.
16. Molnar B, Ladanyi A, Tanko L et al.: Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clin Cancer Res 2001; 7: 4080-85.
17. Vona G, Sabile A, Louha M et al.: Isolation by size of epithelial tumor cells: A new method for the immunomorphological and molecular characterization of circulating tumor cells. Am J Pathol 2000; 156: 57-63.
18. Patent FDA. Medical devices; immunology and microbiology devices; classification of the immunomagnetic circulating cancer cell selection and enumeration system. Final rule. Fed Regist 2004, 69, 26036-38.
19. Wong SC, Chan CM, Ma BB et al.: Clinical significance of cytokeratin 20-positive circulating tumor cells detected by a refined immunomagnetic enrichment assay in colorectal cancer patients. Clin Cancer Res 2009; 15: 1005-12.
20. Welinder C, Jansson B, Lindell G et al.: Cytokeratin 20 improves the detection of circulating tumor cells in patients with colorectal cancer. Cancer Lett. 2014 Dec 17. pii: S0304-3835(14)00779-4. doi: 10.1016/j.canlet.2014.12.024
21. Fujita S, Kudo N, Akasu T et al.: Detection of cytokeratin 19 and 20 mRNA in peripheral and mesenteric blood from colorectal cancer patients and their prognosis. Int J Colorectal Dis 2001; 16: 141-46.
22. Akashi A, Komuta K, Haraguchi M et al.: Carcinoembryonic antigen mRNA in the mesenteric vein is not a predictor of hepatic metastasis in patients with resectable colorectal cancer: a longterm study. Dis Colon Rectum 2003; 46: 1653-58.
23. Bosch B, Guller U, Schnider A et al.: Perioperative detection of disseminated tumor cells is an independent prognostic factor in patients with colorectal cancer. Br J Surg 2003; 90: 882-88.
24. Iinuma H, Okinaga K, Egami H et al.: Usefulness and clinical significance of quantitative real-time RT-PCR to detect isolated tumor cells in the peripheral blood and tumor drainage blood of patients with colorectal cancer. Int J Oncol 2006; 28: 297-306.
25. Ito S, Nakanishi H, Hirai T et al.: Quantitative detection of CEA expressing free tumor cells in the peripheral blood of colorectal cancer patients during surgery with real-time RT-PCR on a Light-Cycler. Cancer Lett 2002; 183: 195-203.
26. Guller U, Zajac P, Schnider A et al.: Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer. Ann Surg 2002; 236: 768-76.
27. Bessa X, Pinol V, Castelli-Bel S et al.: Prognostic value of postoperative detection of blood circulating tumor cells in patients with colorectal cancer operated for cure. Ann Surg 2003; 237: 368-75.
28. Bessa X, Elizalde JI, Boix L et al.: Lack of prognostic influence of circulating tumor cells in peripheral blood of patients with colorectal cancer. Gastroenterology 2001; 120: 1084-92.
29. Peach G, Kim C, Zacharakis E et al.: Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: a systematic review. Br J Cancer 2010; 102: 1327-34.
30. Steinert R, Hantschick M, Vieth M et al.: Influence of subclinical tumor spreading on survival after curative surgery for colorectal cancer. Arch Surg 2008; 143: 122-28.
31. Garrigós N, Gallego J, Guillén-Ponce C et al.: Circulating tumour cell analysis as an early marker for relapse in stage II and III colorectal cancer patients: a pilot study. Clin Transl Oncol 2010; 12: 142-47.
32. Sadahiro S, Suzuki T, Maeda Y et al.: Detection of carcinoembryonic antygen messenger RNA-expressing cells in peripheral blood 7 days after curative surgery is a novel prognostic factor in colorectal cancer. Ann Surg Oncol 2007; 14: 1092-98.
33. Thorsteinsson M, Jess P. The clinical significance of circulating tumor cells in non-metastatic colorectal cancer – A review. Eur J Surg Oncol 2011; 37: 1-7.
34. Koyanagi K, Bilchik AJ, Saha S et al.: Prognostic relevance of occult nodal micrometastases and circulating tumor cells in colorectal cancer in a prospective multicenter trial. Clin Cancer Res 2008; 14: 7391-96
35. Lankiewicz S, Zimmermann S, Hollmann C et al.: Circulating tumour cells as a predictive factor for response to systemic chemotherapy in patients with advanced colorectal cancer. Mol Oncol 2008; 2: 349-55
36. Mescoli C, Albertoni L, Pucciarelli S et al.: Isolated tumor cells in regional lymph nodes as relapse predictors in stage I and II colorectal cancer. J Clin Oncol 2012; 30: 965-71.
37. Rahbari NN, Bork U, Motschall E et al.: Molecular detection of tumor cells in regional lymph nodes is associated with disease recurrence and poor survival in node-negative colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2012; 30: 60-70.
38. Cohen SJ, Punt CJA, Iannotti N et al.: Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 3213-21.
39. Romiti A, Raffa S, Di Rocco R et al.: Circulating tumor cells count predicts survival in colorectal cancer patients J Gastrointestin Liver Dis 2014; 23(3): 279-84.
40. Rahbari NN, Aigner M, Thorlund K et al.: Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology 2010; 138: 1714-26.
41. Hiraiwa K, Takeuchi H, Hasegawa H et al.: Clinical significance of circulating tumor cells in blood from patients with gastrointestinal cancers. Ann Surg Oncol 2008; 15: 3092-3100.
42. Tol J, Koopman M, Miller MC et al.: Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol 2010; 21: 1006-12.
43. Gazzaniga P, Raimondi C, Gradilone A et al.: Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff? J Cancer Res Clin Oncol 2013; 139: 1411-16.
44. Cristofanilli M, Budd GT, Ellis MJ et al.: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351(8): 781-91.
45. Sastre J, Maestro ML, Puente J et al.: Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol 2008; 19: 935-38.
46. Groot Koerkamp B, Rahbari NN, Büchler MW et al.: Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: a meta-analysis. Ann Surg Oncol 2013; 20: 2156-65.